FDA approval of Schering-Plough's Vytorin called key to firm's future

Schering-Plough's chief executive says the approval of Vytorin, a new entrant in the market of cholesterol-lowering drugs, is the key to the future of the company. The approval came at the end of a week when Schering-Plough suffered its fourth consecutive quarterly loss and an expected guilty plea in a $350 million Medicaid fraud suit.

View Full Article in:

Wall Street Journal (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD